Australia markets closed

Geron Corporation (GERN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.3100+0.0100 (+0.30%)
At close: 04:00PM EDT
3.3500 +0.04 (+1.21%)
Pre-market: 05:03AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.3000
Open3.3000
Bid3.2900 x 1700
Ask3.3300 x 8700
Day's range3.1800 - 3.3400
52-week range1.6400 - 3.7400
Volume10,575,785
Avg. volume11,330,568
Market cap1.946B
Beta (5Y monthly)0.55
PE ratio (TTM)N/A
EPS (TTM)-0.3200
Earnings date09 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est5.08
  • Zacks

    Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More

    Geron Corporation (GERN) and Crinetics Pharmaceuticals (CRNX) gain on positive regulatory and study updates.

  • Business Wire

    Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

    FOSTER CITY, Calif., March 19, 2024--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of an underwritten offering consisting of 41,999,998 shares of its common stock at a price of $3.00 per share and pre-funded warrants to purchase 8,002,668 shares of its common stock. The pre-funded warrants are being sold at a price of $2.999 per pre-funded warrant. All of the securities in the offering are to be sold by Geron. The offering included

  • Yahoo Finance Video

    Geron, Madrigal Pharmaceuticals jump on good news from FDA

    Shares of both Geron (GERN) and Madrigal Pharmaceuticals (MDGL) are soaring after receiving positive news from the Food and Drug Administration. For Geron, an FDA advisory panel backed its blood disorder treatment. For Madrigal, the FDA approved its treatment for a liver disease known as nonalcoholic steatohepatitis, or NASH. Yahoo Finance's Josh Lipton and Julie Hyman discuss the stocks' reaction in the video above. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Stephanie Mikulich.